New EU epilepsy approval for UCB

The European Commission has approved Belgian drugmaker UCB's Keppra (levetiracetam) as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy. This new indication represents the fifth EU approval for Keppra in epilepsy, and its second EU approval in a generalized seizure type. The agent is already indicated in Europe as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly-diagnosed epilepsy; adjunctive therapy for partial-onset seizures with or without secondary generalization in adults and children from four years of age with epilepsy; and adjunctive therapy for myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.